Background: A clinical study to investigate the leukotriene B4 (LTB4)-receptor antagonist BIIL 284 in cystic fibrosis (CF) patients was prematurely terminated due to a significantly increased risk of adverse pulmonary events. We aimed to establish the effect of BIIL284 in models of Pseudomonas aeruginosa lung infection, thereby contributing to a better understanding of what could have led to adverse pulmonary events in CF patients. Methods: P. aeruginosa DNA in the blood of CF patients during and after acute pulmonary exacerbations and in stable patients with non-CF bronchiectasis (NCFB) and healthy individuals was assessed by PCR. The effect of BIIL 284 treatment was tested in an agar bead murine model of P. aeruginosa lung infection. Bacterial count and inflammation were evaluated in lung and other organs. Results: Most CF patients (98%) and all patients with NCFB and healthy individuals had negative P. aeruginosa DNA in their blood. Similarly, the P. aeruginosa-infected mice showed bacterial counts in the lung but not in the blood or spleen. BIIL 284 treatment decreased pulmonary neutrophils and increased P. aeruginosa numbers in mouse lungs leading to significantly higher bacteremia rates and lung inflammation compared to placebo treated animals. Conclusions: Decreased airway neutrophils induced lung proliferation and severe bacteremia in a murine model of P. aeruginosa lung infection. These data suggest that caution should be taken when administering anti-inflammatory compounds to patients with bacterial infections.

BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs / G. Doring, A. Bragonzi, M. Paroni, F.-. Akturk, C. Cigana, A. Schmidt, D. Gilpin, S. Heyder, T. Born, C. Smaczny, M. Kohlhaufl, T.O.F. Wagner, M.R. Loebinger, D. Bilton, M.M. Tunney, J.S. Elborn, G.B. Pier, M.W. Konstan, M. Ulrich. - In: JOURNAL OF CYSTIC FIBROSIS. - ISSN 1569-1993. - 13:2(2014 Mar), pp. 156-163. [10.1016/j.jcf.2013.10.007]

BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs

M. Paroni;
2014

Abstract

Background: A clinical study to investigate the leukotriene B4 (LTB4)-receptor antagonist BIIL 284 in cystic fibrosis (CF) patients was prematurely terminated due to a significantly increased risk of adverse pulmonary events. We aimed to establish the effect of BIIL284 in models of Pseudomonas aeruginosa lung infection, thereby contributing to a better understanding of what could have led to adverse pulmonary events in CF patients. Methods: P. aeruginosa DNA in the blood of CF patients during and after acute pulmonary exacerbations and in stable patients with non-CF bronchiectasis (NCFB) and healthy individuals was assessed by PCR. The effect of BIIL 284 treatment was tested in an agar bead murine model of P. aeruginosa lung infection. Bacterial count and inflammation were evaluated in lung and other organs. Results: Most CF patients (98%) and all patients with NCFB and healthy individuals had negative P. aeruginosa DNA in their blood. Similarly, the P. aeruginosa-infected mice showed bacterial counts in the lung but not in the blood or spleen. BIIL 284 treatment decreased pulmonary neutrophils and increased P. aeruginosa numbers in mouse lungs leading to significantly higher bacteremia rates and lung inflammation compared to placebo treated animals. Conclusions: Decreased airway neutrophils induced lung proliferation and severe bacteremia in a murine model of P. aeruginosa lung infection. These data suggest that caution should be taken when administering anti-inflammatory compounds to patients with bacterial infections.
Anti-inflammatory treatment; Cystic fibrosis; Pulmonary infection; Adult; Animals; Anti-Inflammatory Agents; Bacteremia; Disease Models, Animal; Female; Humans; Inflammation; Leukocyte Count; Lung; Male; Mice; Pseudomonas Infections; Receptors, Leukotriene B4; Treatment Outcome; Amidines; Carbamates; Cystic Fibrosis; Neutrophils; Pseudomonas aeruginosa
Settore BIO/19 - Microbiologia Generale
mar-2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
PIIS1569199313001641.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 866.4 kB
Formato Adobe PDF
866.4 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/756385
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 56
social impact